Trial Profile
A Phase II Study Of Temozolomide (SCH 52365) In Subjects With Brain Metastasis From Nonsmall Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 22 May 2017 Status changed from completed to discontinued.
- 22 May 2017 Status changed from completed to discontinued.
- 17 Dec 2009 Actual end date (May 2003) added as reported by ClinicalTrials.gov.